Screener
Core Laboratories CLB CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Core Laboratories in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Core Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 6:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-198109
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Other liabilities | (1,932) | (1,053) |
| Net cash provided by operating activities | 3,965 | 6,660 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Capital expenditures - operations | (3,448) | (2,785) |
| Capital expenditures - rebuilding of Aberdeen facility | (1,443) | (794) |
| Proceeds from insurance recovery - Aberdeen facility | — | 3,121 |
| Proceeds from sale of assets | 1,491 | 1,230 |
| Patents and other intangibles | 9 | — |
Item 1. Financial Statements
FAQ
- What is Core Laboratories's capex?
- Core Laboratories (CLB) reported capex of $3.45M in Q1 2026.
- How has Core Laboratories's capex changed year-over-year?
- Core Laboratories's capex increased by 23.8% year-over-year, from $2.79M to $3.45M.
- What is the long-term trend for Core Laboratories's capex?
- Over 4 years (2021 to 2025), Core Laboratories's capex has grown at a -4.6% compound annual growth rate (CAGR), from $13.54M to $11.21M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Core Laboratories's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude